Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1985 1
1990 3
1991 2
1992 3
1993 1
1994 2
1995 2
1996 5
1997 1
1998 1
2000 2
2001 2
2002 1
2003 1
2006 1
2007 2
2008 1
2009 1
2010 1
2011 2
2012 4
2013 1
2015 2
2018 1
2020 1
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
[Propafenone and flecainide in the therapy of ventricular arrhythmias].
Paperini L, Davini A, Lattanzi F, Topi A, Reisenhofer B, Squarcini G, Paci A, Topi PL. Paperini L, et al. Minerva Cardioangiol. 1995 Oct;43(10):449-57. Minerva Cardioangiol. 1995. PMID: 8819814 Review. Italian.
Flecainide and propafenone are antiarrhythmic drugs of the class 1C (Vaughan and Williams) commonly used for ventricular arrhythmias. ...Patients of group A were randomly assigned to antiarrhythmic treatment (flecainide 150-300 mg/die or propafenone 45 …
Flecainide and propafenone are antiarrhythmic drugs of the class 1C (Vaughan and Williams) commonly used for ventricular arrhy …
A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome.
O'Nunain S, Garratt CJ, Linker NJ, Gill J, Ward DE, Camm AJ. O'Nunain S, et al. Pacing Clin Electrophysiol. 1991 Nov;14(11 Pt 2):2028-34. doi: 10.1111/j.1540-8159.1991.tb02810.x. Pacing Clin Electrophysiol. 1991. PMID: 1721219 Clinical Trial.
The prolongation was significantly greater with flecainide than propafenone (P less than 0.05). Both drugs increased tachycardia cycle length (TCL) from 310 +/- 35 msec to 354 +/- 37 msec (propafenone P less than 0.005) and to 352 +/- 37 msec (flecainide …
The prolongation was significantly greater with flecainide than propafenone (P less than 0.05). Both drugs increased tachycard …
Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators.
Chimienti M, Cullen MT Jr, Casadei G. Chimienti M, et al. Am J Cardiol. 1996 Jan 25;77(3):60A-75A. doi: 10.1016/s0002-9149(97)89119-9. Am J Cardiol. 1996. PMID: 8607393 Clinical Trial.
Initial daily doses were flecainide 200 mg (n = 97) or propafenone 450 mg (n = 103). Dose escalations up to a maximum of flecainide 300 mg/day or propafenone 900 mg/day were permitted after > or = 2 attacks of paroxysmal AF. ...There was an acceptab …
Initial daily doses were flecainide 200 mg (n = 97) or propafenone 450 mg (n = 103). Dose escalations up to a maximum of fl …
Intravenous Flecainide for Emergency Department Management of Acute Atrial Fibrillation.
Markey GC, Salter N, Ryan J. Markey GC, et al. J Emerg Med. 2018 Mar;54(3):320-327. doi: 10.1016/j.jemermed.2017.11.016. J Emerg Med. 2018. PMID: 29269083 Review.
OBJECTIVE: Our aim was to clarify the Level 1 evidence for the use of i.v. flecainide in acute AF. METHODS: We performed a systematic review and meta-analysis of the literature. ...Efficacy was superior to propafenone, amiodarone, procainamide, ibutilide, and sotalo …
OBJECTIVE: Our aim was to clarify the Level 1 evidence for the use of i.v. flecainide in acute AF. METHODS: We performed a systematic …
Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm.
Martínez-Marcos FJ, García-Garmendia JL, Ortega-Carpio A, Fernández-Gómez JM, Santos JM, Camacho C. Martínez-Marcos FJ, et al. Am J Cardiol. 2000 Nov 1;86(9):950-3. doi: 10.1016/s0002-9149(00)01128-0. Am J Cardiol. 2000. PMID: 11053705 Clinical Trial.
In a prospective, single-blind trial, we randomized 150 consecutive symptomatic patients with acute (< or = 48 hours' duration) atrial fibrillation to receive intravenous flecainide, propafenone, or amiodarone. Flecainide and propafenone were admini …
In a prospective, single-blind trial, we randomized 150 consecutive symptomatic patients with acute (< or = 48 hours' duration) atrial fi …
Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
Chimienti M, Cullen MT Jr, Casadei G. Chimienti M, et al. Eur Heart J. 1995 Dec;16(12):1943-51. doi: 10.1093/oxfordjournals.eurheartj.a060852. Eur Heart J. 1995. PMID: 8682031 Clinical Trial.
Patients were treated with an initial daily dose of flecainide 100 mg (n = 72) or propafenone 450 mg (n = 63) for paroxysmal supraventricular tachycardia and flecainide 200 mg (n = 97) or propafenone 450 mg (n = 103) for paroxysmal atrial fibrillation. …
Patients were treated with an initial daily dose of flecainide 100 mg (n = 72) or propafenone 450 mg (n = 63) for paroxysmal s …
Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group.
Aliot E, Denjoy I. Aliot E, et al. Am J Cardiol. 1996 Jan 25;77(3):66A-71A. doi: 10.1016/s0002-9149(97)89120-5. Am J Cardiol. 1996. PMID: 8607394 Clinical Trial.
Neurologic signs, central and peripheral, were mostly encountered in the flecainide group (8.5%), and, gastrointestinal effects were more often reported in the propafenone group (16.7%). In paroxysmal AF and paroxysmal atrial flutter, flecainide and propaf …
Neurologic signs, central and peripheral, were mostly encountered in the flecainide group (8.5%), and, gastrointestinal effects were …
Effects of flecainide and propafenone on systolic performance in subjects with normal cardiac function.
Santinelli V, Arnese M, Oppo I, Matarazzi C, Maione S, Palma M, Giunta A. Santinelli V, et al. Chest. 1993 Apr;103(4):1068-73. doi: 10.1378/chest.103.4.1068. Chest. 1993. PMID: 8131440 Clinical Trial.
Flecainide and propafenone are effective in suppressing both ventricular and supraventricular tachyarrhythmias, but their efficacy is often limited by dose-related side effects. ...A significant increase (p < 0.001) in left ventricular systolic internal diameter …
Flecainide and propafenone are effective in suppressing both ventricular and supraventricular tachyarrhythmias, but their effi …
Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil.
Kingma JH, Suttorp MJ. Kingma JH, et al. Am J Cardiol. 1992 Aug 20;70(5):56A-60A; discussion 60A-61A. doi: 10.1016/0002-9149(92)91079-j. Am J Cardiol. 1992. PMID: 1510000 Clinical Trial.
In the first 40 patients, flecainide and verapamil were evaluated; in the second 50 patients, flecainide and propafenone were compared, both in a single-blind randomized study design. ...Sinus rhythm was attained in 32 of 37 patients (86%) with AF treated wit …
In the first 40 patients, flecainide and verapamil were evaluated; in the second 50 patients, flecainide and propafenone …
Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm.
Kondili A, Kastrati A, Popa Y. Kondili A, et al. Wien Klin Wochenschr. 1990 Sep 14;102(17):510-3. Wien Klin Wochenschr. 1990. PMID: 2124756 Clinical Trial.
The patients were randomized to receive verapamil, 10 mg in 5 minutes (n = 29), flecainide, 2 mg/kg in 10 minutes (n = 20) or propafenone, 2 mg/kg in 10 minutes (n = 20). The 3 treatment groups did not differ significantly regarding patient baseline characteristics. …
The patients were randomized to receive verapamil, 10 mg in 5 minutes (n = 29), flecainide, 2 mg/kg in 10 minutes (n = 20) or prop …
45 results